Treatment of neuropsychiatric conditions associated with multiple sclerosis

References

• Minden SL, Schiffer RB. Affective disorders in multiple sclerosis: review and recommendations for clinical research. Arch. Neurol.47, 98–104 (1990).
   PubMed Web of Science ®Google Scholar
• Feinstein A, Feinstein K, Gray T, O’Connor P. Prevalence and neurobehavioral correlates of pathological laughing and crying in multiple sclerosis. Arch. Neurol.54(9), 1116–1121 (1997).
   PubMed Web of Science ®Google Scholar
• Rao SM. Neuropsychology of multiple sclerosis. Curr. Opin. Neurol.8(3), 216–220 (1995).
   PubMed Web of Science ®Google Scholar
• Schiffer RB, Wineman M, Weitkamp LR. Association between bipolar affective disorder and multiple sclerosis. Am. J. Psychiatry143, 94–95 (1986).
   PubMed Web of Science ®Google Scholar
• Patten SB, Svensen LW, Metz LM. Psychotic disorders in MS: population based-evidence of an association. Neurology65(7), 1123–1125 (2005).
   PubMed Web of Science ®Google Scholar
• First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for Axis 1 DSM-IV Disorders–Patient Edition (SCID-I/P, version 2.0). Biometrics Research Department, New York State Psychiatric Institute, NY, USA (1994).
   Google Scholar
• Benedict RH, Fishman I, McClellan MM, Bakshi R, Weinstock-Guttman B. Validity of the Beck Depression Inventory-Fast Screen in multiple sclerosis. Mult. Scler.9(4), 393–396 (2003).
   PubMed Web of Science ®Google Scholar
• Schiffer RB, Wineman NM. Antidepressant pharmacotherapy of depression associated with multiple sclerosis. Am. J. Psychiatry147, 1493–1497 (1990).
   PubMed Web of Science ®Google Scholar
• Scott TF, Nussbaum P, McConell H, Brill P. Measurement of treatment response to sertraline in depressed multiple sclerosis patients using the Carrol scale. Neurol. Res.17, 421–422 (1995).
   PubMed Web of Science ®Google Scholar
• Scott TF, Allen D, Price TRP, McConnell H, Lang D. Characterization of major depressive symptoms in multiple sclerosis. J. Neuropsychiatry Clin. Neurosci.8, 318–323 (1996).
   PubMed Web of Science ®Google Scholar
• Benedetti F, Campori E, Colombo C, Smeraldi E. Fluvoxamine treatment of major depression associated with multiple sclerosis. J. Neuropsychiatry Clin. Neurosci.16(3), 364–366 (2004).
   PubMed Web of Science ®Google Scholar
• Barak Y, Ur E, Achiron A. Moclobemide treatment in multiple sclerosis patients with comorbid depression: an open-label safety trial. J. Neuropsychiatry Clin. Neurosci.11, 271–273 (1999).
   PubMed Web of Science ®Google Scholar
• Flax JW, Gray J, Herbert J. Effect of fluoxetine on patients with multiple sclerosis. Am. J. Psychiatry148, 1603 (1991).
   PubMed Web of Science ®Google Scholar
• Shafey H. The effect of fluoxetine in depression associated with multiple sclerosis. Can. J. Psychiatry37, 147–148 (1992).
   PubMed Web of Science ®Google Scholar
• Browning WN. Exacerbation of symptoms of multiple sclerosis in a patient taking fluoxetine. Am. J. Psychiatry147, 1089 (1990).
   PubMed Web of Science ®Google Scholar
• Russo S, Boon JC, Korf J, Haagsma EB. Mirtazapine for the treatment of interferon-induced psychopathology. Gen. Hosp. Psychiatry25, 497 (2003).
   PubMed Web of Science ®Google Scholar
• Mattson D, Petrie M, Srivastava DK, McDermott D. Multiple sclerosis. Sexual dysfunction and its response to medications. Arch. Neurol.52(9), 862–868 (1995).
   PubMed Web of Science ®Google Scholar
• Krupp LB, Alvarez LA, LaRocca NG, Scheinberg LC. Fatigue in multiple sclerosis. Arch. Neurol.45, 435–437 (1988).
   PubMed Web of Science ®Google Scholar
• Stahl SM. Essential Psychopharmacology: The Prescriber’s Guide. Cambridge University Press, NY, USA (2005).
   Google Scholar
• Hollon SD, DeRubeis RJ, Evans MD et al. Cognitive therapy and pharmacotherapy for depression: singly and in combination. Arch. Gen. Psychiatr.49, 774–781 (1992).
   PubMed Web of Science ®Google Scholar
• Larcombe NA, Wilson PH. An evaluation of cognitive–behavior therapy for depression in patients with multiple sclerosis. Br. Arch. Intern. Med.145, 366–371 (1984).
   Google Scholar
• Foley FW, Bedell JR, LaRocca NG, Scheinberg LC, Reznikoff M. Efficacy of stress inoculation training in coping with multiple sclerosis J. Consult. Clin. Psychol.55, 919–922 (1987).
   PubMed Web of Science ®Google Scholar
• Crawford JD, McIvor GP. Group psychotherapy benefits in multiple sclerosis. Arch. Phys. Med. Rehab.66, 810–813 (1985).
   PubMed Web of Science ®Google Scholar
• Mohr DC, Likosky W, Bertagnolli A et al. Telephone-administered cognitive-behavioral therapy for the treatment of depressive symptoms in multiple sclerosis. J. Consult. Clin. Psychol.68(2), 356–361 (2000).
   PubMed Web of Science ®Google Scholar
• Mohr DE, Boudewyn AC, Goodkin DE, Bostrom A, Epstein L. Comparative outcomes for individual cognitive-behavior therapy, supportive-expressive group psychotherapy, and sertraline for the treatment of depression in multiple sclerosis. J. Consult. Clin. Psychol.69(6), 942–949 (2001).
   PubMed Web of Science ®Google Scholar
• Mohr DC, Goodkin DE. Treatment of depression in multiple sclerosis: review and meta-analysis. Clin. Psych. Sci. Prac.6(1), 1–9 (1999).
   Web of Science ®Google Scholar
• Minden SL. Psychotherapy for people with multiple sclerosis. J. Neuropsychiatry Clin. Neuroscience4, 1–16 (1992).
   PubMed Web of Science ®Google Scholar
• Mattingly G, Baker K, Zorumski CF, Figiel GS. Multiple sclerosis and ECT: possible value of gadolinium enhanced magnetic resonance scans for identifying high-risk patients. J. Neuropsychiatry Clin. Neurosci.4, 145–151 (1992).
   PubMed Web of Science ®Google Scholar
• Goldman Consensus Group. The Goldman Consensus Statement on Depression in Multiple Sclerosis.Mult. Scler.11, 328–337 (2005).
   PubMed Web of Science ®Google Scholar
• Noy S, Achiron A, Gabbay U et al. A new approach to affective symptoms in relapsing–remitting multiple sclerosis. Comp. Psychiatry36(5), 390–395 (1995).
   PubMed Web of Science ®Google Scholar
• Mohr DC, Cox D, Epstein L, Boudewyn A. Teaching patients to self-inject: pilot study of a treatment for injection anxiety and phobia in multiple sclerosis patients prescribed injectable medications. J. Behav. Ther. Exp. Psychiatry33, 39–47 (2002).
   PubMed Web of Science ®Google Scholar
• Mohr DC, Cox D, Merluzzi N. Self-injection anxiety training: a treatment for patients unable to self-inject injectable medications. Mult. Scler.11(2), 182–185 (2005).
   PubMed Web of Science ®Google Scholar
• Kemp K, Lion JR, Magram G. Lithium in the case of a manic patient with multiple sclerosis – a case report. Dis. Nerv. Syst.38, 210–211 (1977).
   PubMedGoogle Scholar
• Falk WE, Mahnke MW, Poskanzer DC. Lithium prophylaxis of corticotrophin-induced psychosis. JAMA241, 1011–1012 (1979).
   PubMed Web of Science ®Google Scholar
• Minden SL, Orav J, Schildkraut JJ. Hypomanic reactions to ACTH and prednisone treatment for multiple sclerosis. Neurology38, 1631–1634 (1988).
   PubMed Web of Science ®Google Scholar
• Ashgar-Ali AA, Taber K, Hurley RA, Hayman LA. Pure neuropsychiatric presentation of multiple sclerosis. Am. J. Psychiatry161, 226–231 (2004).
   PubMed Web of Science ®Google Scholar
• Solaro C, Brichetto G, Battaglia MA, Uccelli MM, Mancardi GL. Antiepileptic medications in multiple sclerosis: adverse effects in a three-year follow-up study. Neurological Science25, 307–310 (2005).
   PubMed Web of Science ®Google Scholar
• Chong SA, Meng-Ko S. Clozapine treatment of psychosis associated with multiple sclerosis. Can. J. Psychiatry42(1), 90–91 (1997).
   PubMed Web of Science ®Google Scholar
• Pine DS, Douglas CJ, Charles E, Davies M, Kahn D. Patients with multiple sclerosis presenting to psychiatric hospitals. J. Clin. Psychiatry56(7), 297–306 (1995).
   PubMed Web of Science ®Google Scholar
• Davids E, Hartwig U, Gastpar M. Antipsychotic treatment of psychosis associated with multiple sclerosis. Prog. Neuropsychopharmacol. Biol. Psychiatry28, 743–744 (2004).
   PubMed Web of Science ®Google Scholar
• Bloch M, Guhr E, Shalev A. Chlorpromazine prophylaxis of steroid-induced psychosis. Gen. Hosp. Psychiatry16,, 42–44 (1994).
   PubMed Web of Science ®Google Scholar
• Schiffer RB, Herndon RM, Rudick RA. Treatment of pathological laughter and weeping with amitriptyline. N. Engl. J. Med.312, 1480–1482 (1985).
   PubMed Web of Science ®Google Scholar
• Allman P. Drug treatment of emotionalism following brain damage. J. R. Soc. Med.85(7), 423–424 (1992).
   PubMed Web of Science ®Google Scholar
• Robinson RG, Parikh RM, Lipsey JR, Starkstein SE, Price TR. Pathological laughing and crying following stroke: validation of a measurement scale and double-blind treatment study. Am. J. Psychiatry150, 286–293 (1993).
   PubMed Web of Science ®Google Scholar
• Andersen G, Vestergaard K, Riis JO. Citalopram for post-stroke pathological crying. Lancet342, 837–839 (1993).
   PubMed Web of Science ®Google Scholar
• Andersen G, Stylsvig M, Sunde N. Citalopram treatment of traumatic brain damage in a 6-year-old boy. J. Neurotrauma16(4), 341–344 (1999).
   PubMed Web of Science ®Google Scholar
• Seliger GM, Hornstein A, Flax J, Herber J, Schroeder K. Fluoxetine improves emotional incontinence. Brain Inj.6(3), 267–270 (1992).
   PubMedGoogle Scholar
• Iannocone S, Ferini-Strambi L. Pharmacologic treatment of emotional lability. Clin. Neuropharmacol.19(6), 532–535 (1996).
   PubMed Web of Science ®Google Scholar
• Nahas Z, Arlinghaus KA, Kotrla KJ, Clearman RR, George MS. Rapid response of emotional incontinence to selective serotonin reuptake inhibitors. J. Neuropsychiatry Clin. Neurosci.10, 453–455 (1998).
   PubMed Web of Science ®Google Scholar
• Muller U, Murai T, Bauer-Wittmund T, von Cramon DY. Paroxetine versus citalopram treatment of pathological crying after brain injury. Brain Inj.13(10), 805–811 (1999).
   PubMed Web of Science ®Google Scholar
• Udaka F, Yamao S, Nagata H, Nakamura S, Masakuni K. Pathologic laughing and crying treated with levodopa. Arch. Neurol.41, 1095–1096 (1984).
   PubMed Web of Science ®Google Scholar
• Smith RA, Moore SR, Gresham LS, Manley PE, Licht JM. The treatment of affective lability with dextromethorphan. Neurology45(Suppl. 4), A330 (1995).
   Web of Science ®Google Scholar
• Brooks BR, Thisted RA, Appel SH et al. Treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine: a randomized trial. Neurology63, 1364–1370 (2004).
   PubMed Web of Science ®Google Scholar
• Zhang Y, Britto MR, Valderhaug KL, Wedlund PJ, Smith RA. Dextromethorphan: enhancing its systemic availability by way of low dose quinidine-mediated inhibition of cytochrome P4502D6. Clin. Pharmacol. Ther.51(6), 647–655 (1992).
   PubMed Web of Science ®Google Scholar
• Panitch HS, Thisted RA, Smith RA et al. Randomized control trial of dextromethorphan/quinidine for pseudobulbar affect in multiple sclerosis. Ann. Neurol.59, 780–787 (2006).
   PubMed Web of Science ®Google Scholar
• Moore SR, Gresham LS, Bromberg MB, Kasarkis EJ, Smith RA. A self report measure of affective lability. J. Neurol. Neurosurg. Psychiatry63(1), 89–93 (1997).
   PubMed Web of Science ®Google Scholar
• Krupp LB, Elkins LE, Scott SR, Smiroldo J, Coyle PK. Donepezil for the treatment of memory impairment in multiple sclerosis. Neurology52(Suppl. 2), A137 (1999).
   PubMed Web of Science ®Google Scholar
• Greene YM, Tariot PN, Wishart H et al. A 12-week, open trial of donepezil hydrochloride in patients with multiple sclerosis and associated cognitive impairments. J. Clin. Psychopharmacol.20(3), 350–356 (2000).
   PubMed Web of Science ®Google Scholar
• Krupp LB, Christodoulou C, Melville P, Scherl WF, MacAllister WS, Elkins LE. Donepezil improved memory in multiple sclerosis in a randomized clinical trial. Neurology63, 1579–1585 (2004).
   PubMed Web of Science ®Google Scholar
• Rorie KD, Stump DA, Jeffrey DR. Effects of donepezil on cognitive function in patients with multiple sclerosis. Neurology56(Suppl. 3), A99 (2001).
   Google Scholar
• Compendium of Pharmaceuticals and Specialists. The Canadian Drug Reference for Health Professionals. Canadian Pharmaceutical Association, Ottawa, Ontario, Canada (2006).
   Google Scholar
• Fischer JS, Priore RL, Jacobs LD et al. Neuropsychological effects of interferon B-1a in relapsing multiple sclerosis. Ann. Neurol.48, 885–892 (2000).
   PubMed Web of Science ®Google Scholar
• Barak Y, Achiron A. Effect of interferon-b-1b on cognitive functions in multiple sclerosis. Eur. Neurol.47, 11–14 (2002).
   PubMed Web of Science ®Google Scholar
• Pliskin NH, Hamer DP, Goldstein DS et al. Improved delayed visual reproduction test performance in multiple sclerosis patients receiving interferon1. Neurology47(6), 1463–1468 (1996).
   PubMed Web of Science ®Google Scholar
• Rovaris M, Comi G, Rocca MA, Wolinsky JS, Filippi M. The European Glatiramer Acetate Study Group. Short-term brain volume change in relapsing-remitting multiple sclerosis. Brain124, 1803–1812 (2001).
   PubMed Web of Science ®Google Scholar
• Weinstein A, Schwid SI, Schiffer RB, McDermott MP, Giang DW, Goodman AD. Neuropsychologic status in multiple sclerosis after treatment with glatiramer. Arch. Neurol.56, 319–324 (1999).
   PubMed Web of Science ®Google Scholar
• Galetta SL, Markowitz C, Lee AG. Immunomodulatory agents for the treatment of relapsing multiple sclerosis. Arch. Intern. Med.162, 2161–2169 (2002).
   PubMed Web of Science ®Google Scholar
• Olivieri RL, Valentino PR, Romeo N, Quattrone A. Pulsed IV methylprednisolone induces a reversible impairment of memory in patients with relapsing-remitting multiple sclerosis. Acta Neurol. Scand.97, 366–369 (1998).
   PubMed Web of Science ®Google Scholar
• Zivadenov R, Rudick RA, De Masi R et al. Effects of IV methylprednisolone on brain atrophy in relapsing–remitting MS. Neurology57, 1239–1247 (2001).
   PubMed Web of Science ®Google Scholar
• Zephir H, de Seze J, Dujardin K et al. One-year cyclophosphamide treatment combined with methylprednisolone improves cognitive dysfunction in progressive forms of multiple sclerosis. Mult. Scler.11(3), 360–363 (2005).
   PubMed Web of Science ®Google Scholar
• Sailer M, Heinze HJ, Schoenfeld MA, Hauser U, Smid HG. Amantadine influences cognitive processing in patients with multiple sclerosis. Pharmacopsychiatry33(1), 28–37 (2000).
   PubMed Web of Science ®Google Scholar
• Cohen RA, Fisher M. Amantadine treatment of fatigue associated with multiple sclerosis. Arch. Neurol.46(6), 676–680 (1989).
   PubMed Web of Science ®Google Scholar
• Geisler MW, Sliwinski M, Coyle PK, Masur DM, Doscher C, Krupp LB. The effects of amantadine and pemoline on cognitive functioning in multiple sclerosis. Arch. Neurol.53(2), 185–188 (1996).
   PubMed Web of Science ®Google Scholar
• van Diemen HAM, Polman CH, van Dongen TMM et al. The effect of 4-aminopyridine on clinical signs in multiple sclerosis: a randomized, placebo-controlled, double-blind, cross-over study. Ann. Neurol.32, 123–130 (1992).
   PubMed Web of Science ®Google Scholar
• Smits RCF, Emmen HH, Bertelsmann FW, Kulig BM, van Loenen AC, Polman CH. The effects of 4-aminopyridine on cognitive function in patients with multiple sclerosis: a pilot study. Neurology44, 1701–1705 (1994).
   PubMed Web of Science ®Google Scholar
• Rossini PM, Pasqualetti P, Pozzilli C et al. Fatigue in progressive multiple sclerosis: results of a randomized, double-blind, placebo-controlled, crossover trial of oral 4-aminopyridine. Mult. Scler.7(6), 354–358 (2001).
   PubMed Web of Science ®Google Scholar
• Bever CT Jr, Anderson PA, Leslie J et al. Treatment with oral 3, 4 diaminopyridine improves leg strength in multiple sclerosis patients: results of a randomized, double-blind, placebo-controlled, crossover trial. Neurology47(6), 1457–1462 (1996).
   PubMed Web of Science ®Google Scholar
• Lincoln NB, Dent A, Harding J et al. Evaluation of cognitive assessment and cognitive intervention for people with multiple sclerosis. J. Neurol. Neurosurg. Psychiatr.72(1), 93–98 (2002).
   PubMed Web of Science ®Google Scholar
• Solari A, Motta A, Mendozzi L et al. Computer-aided retraining of memory and attention in people with multiple sclerosis: a randomized, double-blind controlled trial. J. Neurol. Sci.222(1–2), 99–104 (2004).
   PubMed Web of Science ®Google Scholar
• Jonsson A, Korfitzan EM, Heltberg A, Ravnborg MH, Byskoz-Ottosen E. Effects of neuropsychological treatment in patients with multiple sclerosis. Acta Neurol. Scand.88, 394–400 (1993).
   PubMed Web of Science ®Google Scholar
• Sadovnik AD, Eisen RN, Ebers GC, Paty DW. Cause of death in patients attending multiple sclerosis clinics. Neurology41, 1193–1196 (1991).
   PubMed Web of Science ®Google Scholar